Cocristales, una alternativa para potenciar la solubilidad de los fármacos y el desarrollo de nuevos medicamentos

Anamaría Urrea Rojas; Jhon Alex González Amaya

doi:10.18359/rfcb.8006

Anamaría Urrea Rojas Universidad El Bosque (Colombia)
Jhon Alex González Amaya Universidad El Bosque (Colombia) https://orcid.org/0000-0002-0605-9877

DOI: https://doi.org/10.18359/rfcb.8006

Palabras clave: Cocristal, Solubilidad, Fármaco, Biodisponibilidad

Resumen Autores/as Descargas Referencias bibliográficas Cómo citar

Resumen

Una de las problemáticas en la industria farmacéutica es la baja biodisponibilidad de algunos fármacos debido a su escasa solubilidad. Este trabajo tuvo como objetivo analizar la cocristalización como una estrategia para mejorar esta propiedad, e identificar sus ventajas y limitaciones frente a otras alternativas. Metodología: Revisión bibliográfica narrativa por medio de una metodología PRISMA en las bases de datos ScienceDirect, PubMed y Scopus, considerando artículos de revisión publicados durante los últimos diez años. Resultados y análisis: Se evidenció, según los hallazgos derivados de la revisión realizada, que la cocristalización permite modificar favorablemente las propiedades fisicoquímicas de los principios activos, incrementando su solubilidad, velocidad de disolución y estabilidad, sin alterar su actividad farmacológica. Asimismo, se encontró que esta técnica ofrece ventajas frente a otras estrategias de mejora de biodisponibilidad, aunque la selección adecuada del coformador y las dificultades asociadas al escalamiento industrial continúan siendo desafíos importantes. Conclusiones: La cocristalización constituye una alternativa prometedora para optimizar el desempeño biofarmacéutico de compuestos poco solubles; sin embargo, se requieren avances tecnológicos y estudios adicionales que faciliten su implementación a escala industrial.

Descargas

Los datos de descargas todavía no están disponibles.

Referencias bibliográficas

[1] H. G. Brittain, “Pharmaceutical cocrystals: the coming wave of new drug substances”, J. Pharm. Sci., vol. 102, n.º 2, pp. 311-317, feb. 2013. https://doi.org/10.1002/jps.23402.

[2] B. Dutt, M. Choudhary y V. Budhwar, “Cocrystallization: an innovative route toward better medication”, J. Rep. Pharm. Sci., vol. 9, n.º 2, pp. 256-270, 2020. https://doi.org/10.4103/jrptps.JRPTPS_103_19.

[3] S. Kalepu y V. Nekkanti, “Insoluble drug delivery strategies: review of recent advances and business prospects”, Acta Pharm. Sin. B, vol. 5, n.º 5, pp. 442-453, sep. 2015. https://doi.org/10.1016/j.apsb.2015.07.003.

[4] S. Emami, M. Siahi-Shadbad, K. Adibkia et al., “Recent advances in improving oral drug bioavailability by cocrystals”, Bioimpacts, vol. 8, n.º 4, pp. 305-320, 2018. https://doi.org/10.15171/bi.2018.33.

[5] D. J. Berry y J. W. Steed, “Pharmaceutical cocrystals, salts and multicomponent systems; intermolecular interactions and property based design”, Adv. Drug Deliv. Rev., vol. 117, pp. 3-24, ago. 2017. https://doi.org/10.1016/j.addr.2017.03.003.

[6] A. Karagianni, M. Malamatari y K. Kachrimanis, “Pharmaceutical cocrystals: new solid phase modification approaches for the formulation of API”, Pharmaceutics, vol. 10, n.º 1, p. 10, ene. 2018. https://doi.org/10.3390/pharmaceutics10010018.

[7] M. Guo, X. Sun, J. Chen et al., “Pharmaceutical cocrystals: a review of preparations, physicochemical properties and applications”, Acta Pharm. Sin. B, vol. 11, n.º 8, pp. 2537-2564, ago. 2021. https://doi.org/10.1016/j.apsb.2021.03.030.

[8] U. Garg y Y. Azim, “Challenges and opportunities of pharmaceutical cocrystals: a focused review on non-steroidal anti-inflammatory drugs”, RSC Med. Chem., vol. 12, n.º 5, pp. 705-721, feb. 2021. https://doi.org/10.1039/D0MD00400F.

[9] P. Cerreia Vioglio, M. R. Chierotti y R. Gobetto, “Pharmaceutical aspects of salt and cocrystal forms of API and characterization challenges”, Adv. Drug Deliv. Rev., vol. 117, pp. 86-110, ago. 2017. https://doi.org/10.1016/j.addr.2017.07.001.

[10] P. V. Patel et al., “A review on increased therapeutical efficiency of drugs by pharmaceutical cocrystal approach”, Int. J. Pharm. Sci. Rev. Res., vol. 16, pp. 140-148, 2012.

[11] A. Ainurofiq, D. Sarono Putro, D. Aqila Ramadhani et al., “A review on solubility enhancement methods for poorly water-soluble drugs”, J. Rep. Pharm. Sci., vol. 10, n.º 1, pp. 137-147, 2021. https://doi.org/10.4103/jrptps.JRPTPS_134_19.

[12] A. M. Healy, Z. A. Worku, D. Kumar et al., “Pharmaceutical solvates, hydrates and amorphous forms: a special emphasis on cocrystals”, Adv. Drug Deliv. Rev., vol. 117, pp. 25-46, ago. 2017. https://doi.org/10.1016/j.addr.2017.03.002.

[13] H. Choudhury, B. Gorain, T. Madheswaran et al., “Drug complexation: implications in drug solubilization and oral bioavailability enhancement”, en Dosage Form Design Considerations, vol. I, Elsevier, 2018, pp. 473-512. https://doi.org/10.1016/B978-0-12-814423-7.00014-9.

[14] K. Pathak, “Effective formulation strategies for poorly water soluble drugs”, en Advances and Challenges in Pharmaceutical Technology: Materials, Process Development and Drug Delivery Strategies, Elsevier, 2021, pp. 181-228. https://doi.org/10.1016/B978-0-12-820043-8.00004-9.

[15] H. Liu, S. Guo, S. Wei et al., “Pharmacokinetics and pharmacodynamics of cyclodextrin-based oral drug delivery formulations for disease therapy”, Carbohydr. Polym., vol. 329, p. 121763, abr. 2024. https://doi.org/10.1016/j.carbpol.2023.121763.

[16] K. U. Khan, M. U. Minhas, S. F. Badshah et al., “Overview of nanoparticulate strategies for solubility enhancement of poorly soluble drugs”, Life Sci., vol. 291, p. 120301, feb. 2022. https://doi.org/10.1016/j.lfs.2022.120301.

[17] S. Salunke, F. O'Brien, D. C. Thiam Tan et al., “Oral drug delivery strategies for development of poorly water soluble drugs in paediatric patient population”, Adv. Drug Deliv. Rev., vol. 190, p. 114507, nov. 2022. https://doi.org/10.1016/j.addr.2022.114507.

[18] P. Tran y J. S. Park, “Application of supercritical fluid technology for solid dispersion to enhance solubility and bioavailability of poorly water-soluble drugs”, Int. J. Pharm., vol. 610, p. 121247, dic. 2021. https://doi.org/10.1016/j.ijpharm.2021.121247.

[19] C. L. N. Vo, C. Park y B. J. Lee, “Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs”, Eur. J. Pharm. Biopharm., vol. 85, n.º 3, pp. 799-813, nov. 2013. https://doi.org/10.1016/j.ejpb.2013.09.007.

[20] S. Kumbham, S. Ajjarapu, B. Ghosh et al., “Current trends in the development of liposomes for chemotherapeutic drug delivery”, J. Drug Deliv. Sci. Technol., vol. 87, p. 104854, 2023. https://doi.org/10.1016/j.jddst.2023.104854.

[21] D. Guimarães, A. Cavaco-Paulo y E. Nogueira, “Design of liposomes as drug delivery system for therapeutic applications”, Int. J. Pharm., vol. 601, p. 120571, may. 2021. https://doi.org/10.1016/j.ijpharm.2021.120571.

[22] M. Dymek y E. Sikora, “Liposomes as biocompatible and smart delivery systems: the current state”, Adv. Colloid Interface Sci., vol. 309, p. 102757, nov. 2022. https://doi.org/10.1016/j.cis.2022.102757.

[23] H. Xue, Y. Ju, X. Ye et al., “Construction of intelligent drug delivery system based on polysaccharide-derived polymer micelles: a review”, Int. J. Biol. Macromol., vol. 254, pt. 3, p. 128048, ene. 2024. https://doi.org/10.1016/j.ijbiomac.2023.128048.

[24] Food and Drug Administration, Regulatory Classification of Pharmaceutical Co-Crystals, Guidance for Industry. U.S. Department of Health and Human Services, 2018, pp. 1-4. Disponible en: https://www.federalregister.gov/documents/2018/02/15/2018-03133/regulatory-classification-of-pharmaceutical-co-crystals-guidance-for-industry-availability

[25] A. Borovyef y R. Ozerov, Physchem, 2007.

[26] CIRCE Scientific, “Cocrystal technology”. Disponible en: https://www.circescientific.com/en/our-technology-cocrystal-engineering/.

[27] A. Urrea y J. González, “Cocristalización, una herramienta efectiva para mejorar la solubilidad y biodisponibilidad de los fármacos”, trabajo de grado, Universidad El Bosque, 2024. Disponible en: https://repositorio.unbosque.edu.co/items/5de2a963-bc68-41bb-849e-0938426145fb

[28] G. Bolla y A. Nangia, “Pharmaceutical cocrystals: walking the talk”, Chem. Commun. (Camb.), vol. 52, n.º 54, pp. 8342-8360, jun. 2016. https://doi.org/10.1039/C6CC02943D.

[29] N. Wang, C. Xie, H. Lu et al., “Cocrystal and its application in the field of active pharmaceutical ingredients and food ingredients”, Curr. Pharm. Des., vol. 24, n.º 21, pp. 2339-2348, 2018. https://doi.org/10.2174/1381612824666180522102732.

[30] M. Karimi-Jafari, L. Padrela, G. M. Walker et al., “Creating cocrystals: a review of pharmaceutical cocrystal routes and applications”, Cryst. Growth Des., vol. 18, n.º 10, pp. 6370-6387, 2018. https://doi.org/10.1021/acs.cgd.8b00933.

[31] O. Almarsson y M. J. Zaworotko, “Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?”. Chem. Commun. (Camb.), n.º 17, pp. 1889-1896, sep. 2004. https://doi.org/10.1039/b402150a.

[32] S. P. Bhardwaj y S. L. Morissette, “Impact of cocrystallization on pharmaceutical properties”, Curr. Opin. Solid State Mater. Sci., vol. 19, n.º 5, pp. 327-339, 2015.

[33] J. Pantwalawalkar, N. Kale, S. Nangare et al., “Pharmaceutical cocrystals: unlocking the potential of challenging drug candidates”, J. Drug Deliv. Sci. Technol., vol. 104, p. 106572, 2025. https://doi.org/10.1016/j.jddst.2024.106572.

[34] P. S. Panzade y G. R. Shendarkar, “Pharmaceutical cocrystal: a game changing approach for the administration of old drugs in new crystalline form”, Drug Dev. Ind. Pharm., vol. 46, n.º 10, pp. 1559-1568, oct. 2020. https://doi.org/10.1080/03639045.2020.1810270.

[35] R. Thakuria, A. Delori, W. Jones et al., “Pharmaceutical cocrystals and poorly soluble drugs”, Int. J. Pharm., vol. 453, n.º 1, pp. 101-125, ago. 2013. https://doi.org/10.1016/j.ijpharm.2012.10.043.

[36] J. W. Steed, “The role of co-crystals in pharmaceutical design”, Trends Pharmacol. Sci., vol. 34, n.º 3, pp. 185-193, mar. 2013. https://doi.org/10.1016/j.tips.2012.12.003.

[37] A. Kumar y A. Nanda, “In-silico methods of cocrystal screening: a review on tools for rational design of pharmaceutical cocrystals”, J. Drug Deliv. Sci. Technol., vol. 63, p. 102527, 2021. https://doi.org/10.1016/j.jddst.2021.102527.

[38] P. Sarathi y S. Padhi, “Insight of the various in silico screening techniques developed for assortment of cocrystal formers and their thermodynamic characterization”, Drug Dev. Ind. Pharm., vol. 47, n.º 10, pp. 1523-1534, oct. 2021. https://doi.org/10.1080/03639045.2022.2042554.

[39] S. A. Ross, D. A. Lamprou y D. Douroumis, “Engineering and manufacturing of pharmaceutical co-crystals: a review of solvent-free manufacturing technologies”, Chem. Commun. (Camb.), vol. 52, n.º 57, pp. 8772-8786, jul. 2016. https://doi.org/10.1039/C6CC01289B.

[40] R. A. Saindane y N. A. Thombre, “Drug-drug cocrystals: a promising approach to overcome barriers in pain management”, Cryst. Res. Technol., vol. 58, n.º 7, p. 2300029, 2023. https://doi.org/10.1002/crat.202300029.

[41] M. Rodrigues, B. Baptista, J. A. Lopes et al., “Pharmaceutical cocrystallization techniques. Advances and challenges”, Int. J. Pharm., vol. 547, n.º 1-2, pp. 404-420, ago. 2018. https://doi.org/10.1016/j.ijpharm.2018.06.024.

[42] R. Kumar Bandaru, S. Rekha, G. Kenguva et al., “Recent advances in pharmaceutical cocrystals: from bench to market”, Front. Pharmacol., vol. 12, p. 780582, nov. 2021. https://doi.org/10.3389/fphar.2021.780582.

[43] N. Qiao, M. Li, W. Schlindwein et al., “Pharmaceutical cocrystals: an overview”, Int. J. Pharm., vol. 419, n.º 1-2, pp. 1-11, oct. 2011. https://doi.org/10.1016/j.ijpharm.2011.07.037.

[44] D. Douroumis, S. A. Ross y A. Nokhodchi, “Advanced methodologies for cocrystal synthesis”, Adv. Drug Deliv. Rev., vol. 117, pp. 178-195, ago. 2017. https://doi.org/10.1016/j.addr.2017.07.008.

[45] C. Pando, A. Cabañas y I. A. Cuadra, “Preparation of pharmaceutical co-crystals through sustainable processes using supercritical carbon dioxide: a review”, RSC Adv., vol. 6, n.º 75, pp. 71134-71150, 2016. https://doi.org/10.1039/C6RA10917A.

[46] A. O’Sullivan, B. Long, V. Verma et al., “Solid-state and particle size control of pharmaceutical cocrystals using atomization-based techniques”, Int. J. Pharm., vol. 621, p. 121798, jun. 2022. https://doi.org/10.1016/j.ijpharm.2022.121798.

[47] R. K. Kankala, P. Y. Xu, B. Q. Chen et al., “Supercritical fluid (SCF)-assisted fabrication of carrier-free drugs: an eco-friendly welcome to active pharmaceutical ingredients (API)”, Adv. Drug Deliv. Rev., vol. 176, p. 113846, sep. 2021. https://doi.org/10.1016/j.addr.2021.113846.

[48] L. Padrela, M. A. Rodrigues, A. Duarte et al., “Supercritical carbon dioxide-based technologies for the production of drug nanoparticles/nanocrystals: a comprehensive review”, Adv. Drug Deliv. Rev., vol. 131, pp. 22-78, jun. 2018. https://doi.org/10.1016/j.addr.2018.07.010.

[49] T. Kendall, S. Stratford, A. R. Patterson et al., “An industrial perspective on co-crystals: screening, identification and development of the less utilised solid form in drug discovery and development”, en Progress in Medicinal Chemistry, vol. 60, Elsevier B.V., 2021, pp. 345-442.

[50] O. N. Kavanagh, D. M. Croker, G. M. Walker et al., “Pharmaceutical cocrystals: from serendipity to design to application”, Drug Discov. Today, vol. 24, n.º 3, pp. 796-804, mar. 2019. https://doi.org/10.1016/j.drudis.2018.11.023.

[51] M. Banerjee, K. Nimkar, S. Naik et al., “Unlocking the potential of drug-drug cocrystals: a comprehensive review”, J. Control. Release, vol. 348, pp. 456-469, ago. 2022. https://doi.org/10.1016/j.jconrel.2022.06.003.

Cómo citar

Urrea Rojas, A., & González Amaya, J. A. (2026). Cocristales, una alternativa para potenciar la solubilidad de los fármacos y el desarrollo de nuevos medicamentos. Revista Facultad De Ciencias Básicas, 20(1). https://doi.org/10.18359/rfcb.8006